LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

DocGo Announces Attendance at November 2023 Investor Conferences

November 08, 2023 | Last Trade: US$1.30 0.03 2.36

NEW YORK / Nov 08, 2023 / Business Wire / DocGo, a leading provider of technology-enabled mobile health services (Nasdaq: DCGO), today announced that the company will be participating in the following investor conferences during the month of November.

Needham & Company 4th Annual Tech Week

November 15, 2023 – Virtual 1x1 investor meetings, contact your Needham representative for additional information.

Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

November 16, 2023 – 1x1 investor meetings, contact your Canaccord representative for additional information.

BTIG Digital Health Forum

November 20, 2023 – Virtual 1x1 investor meetings, contact your BTIG representative for additional information.

About DocGo

DocGo is leading the proactive health care revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring, and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With mobile health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page